Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Leqvio Market Between 2025 and 2034?

In recent years, the market size of leqvio has achieved XX (CAGR). Projected growth indicates a rise from $XX million in 2024 to $XX million in 2025, representing a compound annual growth rate (CAGR) of XX%. Several factors are driving this growth witnessed in the historic period. These include an increase in funding for RNA-based drug innovation, rising expenditure on cholesterol control medications, elevated investment in research and development for new medicinal options, growing awareness about healthcare, and a surge in demand for specialised medications.

The expansion of the leqvio market is projected to experience an XX% Compound Annual Growth Rate (CAGR) in the forthcoming years, escalating to a worth of $XX million in 2029. The global increase in cardiovascular diseases, heightened awareness of PCSK9 inhibitors effectiveness, rising incidents of elevated cholesterol levels, a surge in the elderly populace, along with the development of biologic drugs, all contribute to the expected growth during the forecast timeframe. The forecast period also sees a growing appetite for sophisticated treatments for hypercholesterolemia, ongoing research broadening indications, steady upgrades from regulatory authorities such as the FDA, advancement in biopharmaceutical research, and drug development progression.

What Strategic Factors Are Influencing the Accelerated Growth of the Leqvio Market?

The rise in occurrences of cardiovascular ailments is anticipated to fuel the expansion of the leqvio market. Heart diseases and conditions affecting blood vessels, such as high blood pressure, heart attacks, and strokes fall under cardiovascular conditions. Lifestyle factors like an unhealthy diet, lack of physical activity, overconsumption of alcohol, and diabetes, along with aging, increase the risk. Leqvio is used to inhibit the PCSK9 protein, increasing the efficiency of the liver in removing LDL cholesterol from the bloodstream, lowering LDL levels which in turn, limits the chances of cardiovascular encounters. For context, data shared by the British Heart Foundation, a cardiovascular research charity based in the UK, reported in September 2024, that approximately 7.6 million people in the UK are living with heart and circulatory diseases, including nearly 4 million men and 3.6 million women. Cardiovascular ailments account for nearly 27% of all deaths in the UK, meaning over 170,000 deaths each year, or roughly 480 deaths daily, or one death every three minutes. Hence, the escalating prevalence of cardiovascular diseases is contributing to the growth of the Leqvio market.

Get Your Free Sample of the Global Leqvio Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Are the Key Firms That Are Driving Transformation in the Leqvio Market?

Major companies operating in the leqvio market include Novartis AG

What Current Trends in the Leqvio Market Should Industry Players Pay Attention To?

One significant movement in the leqvio market revolves around the conceptualization and production of superior injectable prescription drugs. These are designed to offer enduring therapies, enhancing patient compliance and health outcomes. Injectable prescription medication is usually required in managing elevated cholesterol levels and mitigating the risks associated with cardiovascular conditions. They are administered periodically to maintain beneficial therapeutic effects. Take, for example, Novartis, a Switzerland-based pharmaceutical firm that had its Leqvio (inclisiran) label updated by the US Food and Drug Administration (FDA) in July 2023. This update allows its administration at an earlier stage for patients grappling with elevated LDL-C and a higher risk of cardiac disease, on top of diet and statin therapy. It yields a 52% reduction in LDL-C with two doses annually following two starter doses, demonstrating effectiveness in patients who can’t attain the LDL-C target despite statin therapy. The VictORION clinical trial program backs this update with substantial safety and effectiveness outcomes.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Are Market Segments in the Leqvio Industry Positioned for Long-Term Growth?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Regions Are Driving Expansion in the Leqvio Market?

North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Parameters Define the Leqvio Market’s Scope?

Leqvio is an siRNA-based therapy that reduces low-density lipoprotein (LDL) cholesterol by silencing the mRNA responsible for PCSK9 production in the liver. It improves the liver’s ability to clear LDL-C from the bloodstream, lowering the risk of heart attacks, strokes, and other cardiovascular events in high-risk patients.

Browse Through More Similar Reports By The Business Research Company:

Cholesterol Test Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cholesterol-test-global-market-report

Body Fat Reduction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/body-fat-reduction-global-market-report

Fatty Liver Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: